Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( KRW)
Sales 2017 909 B
EBIT 2017 442 B
Net income 2017 345 B
Debt 2017 204 B
Yield 2017 0,01%
Sales 2018 1 273 B
EBIT 2018 656 B
Net income 2018 503 B
Debt 2018 62,5 B
Yield 2018 0,01%
P/E ratio 2017 53,05
P/E ratio 2018 37,59
EV / Sales2017 19,9x
EV / Sales2018 14,1x
Capitalization 17 905 B
More Financials
Company
Celltrion, Inc. engages in the development, manufacture, and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs, and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
09/14 Roche faces prospect of second Rituxan biosimilar in US
09/06 CELLTRION : 82% of Celltrions Sales Revenues Come from Internal Dealings
08/10 CELLTRION : and Teva Announce U.S. FDA Acceptance of Biologics License Applicati..
08/02 CELLTRION : FDA accepts Celltrions BLA for breast cancer biosimilar
08/01 TEVA PHARMACEUTICAL INDUSTRIES LTD : . - Celltrion and Teva Announce U.S. FDA Ac..
06/22 CELLTRION : "Human Monoclonal Antibodies Derived from Human B Cells and Having N..
05/26 CELLTRION : Why biosimilars are changing the pharmaceutical industry
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
04/28 Celltrion wins Herceptin patent trials against Roche in Korea
04/07 CELLTRION : George Steuart Health partners with Celltrion Healthcare to launch f..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137 650  KRW
Spread / Average Target -5,7%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Joseph Lee Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.15 738
INCYTE CORPORATION14.56%24 235
QUINTILES IMS HOLDINGS INC24.44%20 267
LONZA GROUP57.01%19 853
ALNYLAM PHARMACEUTICALS, INC.204.06%10 359
ALKERMES PLC-8.85%7 735